The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010875-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Assess the effect of BHQ880 compared with placebo on time to first SRE in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone


Critère d'inclusion

  • Patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy